Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Thomas C. Abshire MD
Professor
Department of Pediatrics
Division of Hematology/Oncology

OFFICE ADDRESS:
MACC Fund Research Center
8701 Watertown Plank Rd
Milwaukee, WI 53226

EDUCATION:
7/1971 - 6/1975 BS, USAF Academy, Colorado Springs, CO
8/1975 - 5/1979 MD, Tulane University School of Medicine, New Orleans, LA

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
7/1979 - 6/1982 Resident, Pediatrics, David Grant USAF Medical Center, Travis AFB, CA
7/1985 - 6/1988 Fellow, Pediatrics, Hematology/Oncology, University of Colorado Health Sciences Center, Denver, CO

MILITARY SERVICE:
6/1975 - 9/1995 United States Air Force, Lt Colonel, Retired

FACULTY APPOINTMENTS:
7/1989 - 7/1985 Clinical Assistant Professor, Pediatrics, University of Southern Alabama College of Medicine, Mobile, AL
7/1989 - 7/1994 Clinical Assistant Professor, Pediatrics, F. Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD
7/1994 - 9/1995 Associate Professor, Clinical Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD
9/1995 - 8/2003 Associate Professor, Pediatrics, Emory University School of Medicine, Atlanta, GA
9/2003 - 10/2009 Professor, Pediatrics, Emory University School of Medicine, Atlanta, GA
10/2009 - Present Senior Investigator, Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI
7/2010 - Present Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
5/2011 - Present Professor, Medicine, Medical College of Wisconsin, Milwaukee, WI

ADMINISTRATIVE APPOINTMENTS:
8/1982 - 5/1985 Pediatric Consultant, Child Protective Service, Eglin Air Force Base, FL
7/1988 - 8/1995 Chief, Pediatrics, Hematology/Oncology, Keesler USAF Medical Center, Keesler Air Force Base, MS
7/1989 - 8/1995 Director, Special Coagulation Laboratory, Keesler USAF Medical Center, Keesler Air Force Base, MS
7/1993 - 9/1995 Consultant to the Air Force Surgeon General, Pediatrics, Hematology/Oncology, United States Air Force,
1/1999 - 10/2009 Medical Director, Hemophilia Branch, Region IV South and Hemophilia of Georgia, Inc., Maternal & Child Health Bureau, GA
11/2006 - 10/2009 Director's Chair in Hemostasis, Hemophilia of Georgia, Inc., GA
10/2009 - Present Senior Vice President, Medical Sciences Institute and Chief Medical Officer, BloodCenter of Wisconsin, Milwaukee, WI

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
6/1984 - 5/1985 Director, Pediatric Education, Family Practice Teaching Program, Eglin, Pediatrics, USAF Regional Hospital, FL
7/1990 - 8/1995 Associate Residency Program Director, Pediatrics, Keesler USAF Medical Center, MS
6/1996 - 6/2009 Education Coordinator, Pediatrics, Hematology/Oncology, Emory University School of Medicine, GA
6/1996 - 6/2009 Fellowship Director, Pediatrics, Hematology/Oncology, Emory University School of Medicine, GA

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
7/1983 - 5/1985 Director, Newborn Services, Elgin USAF Regional Hospital, Eglin Air Force Base, FL
7/1988 - 8/1995 Chief, Pediatrics, Hematology/Oncology, Keesler USAF Medical Center, Keesler Air Force Base, MS
7/1989 - 8/1995 Director, Special Coagulation Laboratory, Keesler USAF Medical Center, Keesler Air Force Base, MS
7/1990 - 8/1995 Member, Pathology, Keesler USAF Medical Center, Keesler Air Force Base, MS
9/1995 - 9/2007 Director, Special Coagulation Laboratory, Children's Healthcare of Atlanta, Atlanta, GA
1/1999 - 10/2009 Director, Comprehensive Hemophilia Program, Emory University, GA
1/2000 - 12/2004 Vice Section Chief, Hematology/Oncology, Children's Healthcare of Atlanta, Egleston, GA

RESEARCH ADMINISTRATIVE APPOINTMENTS:
7/1988 - 8/1995 Principal Investigator, Pediatric Oncology Group, Keesler USAF Medical Center, Keesler Air Force Base, MS
7/1989 - 8/1995 Research and Education Coordinator, Pediatric Department, Keesler USAF Medical Center, Keesler Air Force Base, MS
7/1989 - 7/1995 Associate Scientist, Comprehensive Sickle Cell Center, University of South Alabama, Mobile, AL

HOSPITAL STAFF PRIVILEGES:
8/1982 - 6/1985 Attending Physician, Pediatrics, Eglin Hospital, Eglin Air Force Base, FL
7/1988 - 8/1995 Attending Physician, Pediatrics, Keesler Medical Center, Keesler United States Air Force Base, MS
9/1995 - 10/2009 Attending Physician, Pediatrics, Hematology/Oncology, Children's Healthcare of Atlanta - Egleston, Scottish Rite, and Hughes Spalding, Atlanta, GA
9/1995 - 10/2009 Attending Physician, Pediatrics, Hematology/Oncology, Grady Hospital, Crawford Long Hospital, and Emory University Hospital, Atlanta, GA
8/2010 - Present Attending Physician, Pediatrics, Hematology, Children's Hospital of Wisconsin, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
Pediatrics
2/13/1983
None
Pediatric Hematology-Oncology
7/10/1987
None
 
Licensure
Number Issue DateExpiration
California License
A-36740 Inactive
1981
None
Colorado License
26782 Inactive
1985
None
Georgia License
039990
1995
None
Wisconsin License
54405-020
2010
10/31/2011
 
AWARDS AND HONORS:
1975 Distinguished Graduate (Magna Cum Laude), US Air Force Academy
1984 Outstanding Teacher Award, Family Practice Teaching Program, Eglin AFB Regional Hospital
1987 - 1988 Finalist for the Andrew Margileth Clinical Research Award, Uniformed Services Pediatrics
1990 Golden Apple Award for Teaching Excellence, Department of Pediatrics, Keesler USAFB Medical Center
1992 Finalist for the Andrew Margileth Clinical Research Award, Uniformed Services Pediatrics
1995 Medical Student Teacher of the Year for Pediatric Clerkship, Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine
1997 Outstanding Medical Service Award, Georgia Hemophilia Community
1/2005 - 5/2005 Selection to Pediatric Executive Program, Emory University School of Medicine
11/2006 Director's Chair in Hemostasis, Hemophilia of Georgia, Inc.
2009 - 2011 Best Doctors in America

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
1984 - Present American Academy of Pediatrics (AAP) (Fellow)
1992 - Present American Society of Hematology (ASH) (Fellow)
1993 - 1995 Uniformed Services Section of American Academy of Pediatrics (AAP) (Executive Committee Member)
1995 - Present National Hemophilia Foundation (NHF) (Member)
1996 - Present Hemophilia Thrombosis Research Society (HTRS) (Member)
1996 - 2005 The American Society of Clinical Oncology (ASCO) (Member)
1996 - Present The American Society of Pediatric Hematology/Oncology (ASPHO) (Member)
1998 - Present World Federation of Hemophilia (WFH) (Member)
1998 - Present International Society of Thrombosis and Hemostasis (ISTH) (Member)
2002 - Present Society for Pediatric Research (SPR) (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorship
2009 Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects
Journal Review
1998 - Present Journal of Pediatric Hematology Oncology/Pediatric Blood and Cancer
1998 - Present Journal of Pediatrics
1999 - Present Thrombosis and Haemostasis/J Thrombosis and Haemostasis
2000 - Present Blood

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
8/1982 - 5/1985 Member, Child Advocacy Committee, Eglin USAF Regional Hospital
6/1984 - 5/1985 Member, Residency Review Committee, Eglin USAF Regional Hospital
8/1988 - 8/1995 Member, Tumor Board, Keesler USAF Medical Center
8/1988 - 6/1992 Member, Blood Utilization and Surgical Case Review Committee, Keesler USAF Medical Center
8/1988 - 8/1992 Member, Institutional Review Board, Keesler USAF Medical Center
8/1988 - 8/1995 Member, Cancer Activities Committee, Keesler USAF Medical Center
8/1994 - 8/1995 Member, Institutional Review Board, Keesler USAF Medical Center
8/1996 - 8/1998 Ethics Facilitator, Medical Students Core Pediatric Rotation, Emory University Hospital
9/1996 - 9/2004 Member, Residency Advisory Committee, Department of Pediatrics, Emory University School of Medicine
9/1996 - 9/2003 Member, Resident Selection Committee, Department of Pediatrics, Emory University School of Medicine
3/2001 - 9/2007 Member, Graduate Medical Education Committee, Emory University School of Medicine

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
1990 - 1992 Annual Judge, Howard Johnson, Andrew Margileth, and Ogdon Bruton Research Awards, Uniformed Services Pediatric Section
4/1991 - 4/2002 Member, Relapsed Leukemia Committee, Pediatric Oncology Group (POG) & Children's Oncology Group (COG)
1992 Chairperson, Scientific Awards Committee for Military Pediatrics Research Competition
1996 Annual Judge, Howard Johnson, Andrew Margileth, and Ogdon Bruton Research Awards, Uniformed Services Pediatric Section
3/1998 - 10/2009 Member, Executive Committee, Hemophilia Region IV S
5/1998 - 5/2009 Chairperson (5/2002-5/2008), Training Subcommittee, American Society of Pediatric Hematology/Oncology (ASPHO)
1998 Organizer, 2nd Radionuclide Synovectomy Working Group, Emory University School of Medicine
12/1999 - 5/2002 Member, Hemostasis Subcommittee, Hemophilia Research Society
1999 - 2005 Member, National Advisory Board, Wyeth
1999 Member, National Advisory Board, Center for Disease Control (CDC)
1999 - 2000 Member, National Advisory Board, American Red Cross
1999 - 2009 Member, National Advisory Board, Novo Nordisk
1999 - 2007 Member, National Advisory Board, Bayer
1999 - Present Member, National Advisory Board, Aventis/ZLB Behring/CSL Behring
12/2000 - 4/2008 Member, Board of Directors, Hemophilia and Thrombosis Research Society (HTRS)
7/2001 - 10/2009 Member, Steering Committee, International Immune Tolerance Study
2001 - 2004 Member, National Advisory Board, Baxter
2001 - Present Hemophilia Forum
5/2002 - 11/2010 Member, Medical and Scientific Advisory Council (MASAC), National Hemophilia Foundation (NHF)
5/2002 - 12/2005 President, Hemophilia and Thrombosis Research Society (HTRS)
5/2002 - 5/2005 Member, Board of Directors, American Society of Pediatric Hematology/Oncology (ASPHO)
6/2002 - 1/2007 Member, Uniform Data Collection Committee, Center for Disease Control (CDC)
2002 Organizer, Investigator Meeting: Randomized treatment of early target joint bleeding in children, National Hemophilia Foundation Annual Meeting
2003 Abstract Reviewer, Pediatric Hematology Oncology Section, Annual Society for Pediatric Research (SPR) Meeting
2004 Abstract Reviewer, American Society of Hematology (ASH) Annual Meeting
1/2005 - 12/2006 Member, Scientific Committee on Pediatric Hematology, American Society of Hematology (ASH)
2005 Coordinating Reviewer, American Society of Hematology (ASH) Annual Meeting
1/2006 - Present Co-Chair, Scientific and Standardization Subcommittee on von Willebrand Factor, International Society of Thrombosis and Hemostasis (ISTH)
3/2006 - Present Board Member, American Thrombosis and Hemostasis Network (ATHN)
9/2006 - 3/2010 Member, Council of Pediatric Subspecialties (CoPS)
1/2007 - Present Member, Committee on Training, American Society of Hematology (ASH)
2007 Abstract Reviewer, American Society of Hematology (ASH) Annual Meeting
10/2008 - 10/2010 Member, Section of Hematology/Oncology, American Academy of Pediatrics (AAP)
2008 Abstract Reviewer, Pediatric Hematology Oncology Section, Society for Pediatric Research (SPR)
2008 Study Section, Clinical Research Training Institute (CRTI), American Society of Hematology (ASH)
1/2009 - 12/2010 Chair, American Thrombosis and Hemostasis Network (ATHN)
2009 - 2010 Study Section, Mentor Award, American Society of Hematology (ASH)
2009 Member, National Advisory Board, Bayer
2011 - Present Study Section, Review Committee, Clinical Translational Science Institute of SE WI KL2

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Non-Peer Review
Title:
von Willebrand Disease Prophylaxis Network (VWD PN) and the VWD International Prophylaxis (VIP) Study
Source:
Rho, Inc
Role:
Co-Principal Investigator
PI:
Abshire, Thomas C (Co-PI) and Berntorp, Erik (Co-PI)
Dates:
7/1/2006 - Present
 
Pending
Peer Review
Title:
Comparative Effectiveness in the Diagnosis of VWD
Source:
NIH R01
Role:
Co-Principal Investigator
PI:
Montgomery, Robert R and Abshire, Thomas C (Multiple PIs)
Dates:
12/1/2011 - 11/30/2016
 
Prior
Peer Review
Title:
Comprehensive Care Grant
Source:
MCHB Hemophilia Program
Role:
Principal Investigator
PI:
Abshire, Thomas C
Dates:
1/1999 - 10/2009
 
Title:
Molecular Biology of VWD
Source:
NHLBI
Role:
Co-Principal Investigator
Dates:
7/2005 - 6/2010
 
Title:
Universal Data Collection Inhibitor Sub-Study
Source:
CDC Foundation
Role:
Principal Investigator
PI:
Abshire, Thomas C
Dates:
4/16/2007 - 10/15/2009
 
Title:
Transfusion Medicine Hemostasis Clinical Research Network
Source:
NHLBI
Role:
Principal Investigator
PI:
Abshire, Thomas
Dates:
9/30/2007 - 9/29/2009
 
Title:
Training in Adult and Pediatric Benign Hematology
Source:
American Society of Hematology (ASH)
Role:
Principal Investigator
PI:
Abshire, Thomas C
Dates:
7/1/2008 - 8/31/2009
 
Title:
Universal Data Collection; Prevention of the Complications of Hemophilia Through Hemophilia Treatment Centers
Source:
CDC
Role:
Principal Investigator for Research Activities of Region IV South
PI:
Abshire, Thomas C
Dates:
9/30/2008 - 9/29/2009
 
Non-Peer Review
Title:
Prospective Evaluation of Bleeding Disorders in Children
Source:
Association of Teachers of Preventative Medicine (ATSDR); CDC
Role:
Principal Investigator
PI:
Abshire, Thomas C
Dates:
5/1/2002 - 9/30/2005
 
Title:
HOG Comprehensive Care/Programmatic Support Hemophilia Program Grants
Source:
Hemophilia of Georgia, Inc.
Role:
Principal Investigator
PI:
Abshire, Thomas C
Dates:
7/1/2009 - 10/15/2009
 
INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
1. Disseminated Intravascular Coagulation, Pediatric Grand Rounds, University of Mississippi Medical Center, Jackson, MS, 1/1989
2. The Approach to the Bleeding Patient, Pediatric Grand Rounds, University of South Alabama School of Medicine, Mobile, AL, 12/1992
3. Four - 1 hour lectures - A Pediatrician's Approach to Evaluation of Anemia, Sickle Cell Disease, The Bleeding Patient, and Thrombocytopenia and ITP, Annual Pediatric Conference, Department of Family Practice, Eglin Air Force Base, FL, 2/1994
4. Thrombosis in Children and Adolescents, Pathology Grand Rounds, Wilford Hall USAF Medical Center, Lackland AFB, TX, 5/1995
5. Approach to the Bleeding Patient: Laboratory Pearls and Perils, Visiting Professor, LSU Children’s Hospital, New Orleans, LA, 9/1995
6. The Anemia of Inflammation, a Common Cause of Childhood Anemia, Pediatric Grand Rounds, Egleston Children’s Hospital, Atlanta, GA, 1/1996
7. Childhood ALL, Pediatric Grand Rounds, Hughes Spalding Children’s Hospital, Atlanta, GA, 4/1996
8. PEG-Asp in Relapsed ALL, Hematology/Oncology Grand Rounds, Emory University School of Medicine, Atlanta, GA, 11/1996
9. Bruising in children: When to worry; when to refer, Frontiers in Pediatrics Annual Course, Emory/Egleston, Atlanta, GA, 5/1997
10. Wilm’s Tumor, Pediatric Grand Rounds, Hughes Spalding Children’s Hospital, Atlanta, GA, 8/1997
11. Childhood Anemia: The Thinking Pediatrician's Approach, Pediatric Grand Rounds, Egleston Children’s Hospital, Atlanta, GA, 9/1997
12. Bruising in Children: When is it non-accidental trauma?, Current Issues in Child Abuse, Emory/Egleston, Atlanta, GA, 9/1998
13. Leukemia Relapse in Children - A Treatable Malignancy?, Pediatric Grand Rounds, University of Florida, Gainesville, FL, 2/1999
14. Thrombosis in Children: Rarely encountered and Infrequently Explored, Pediatric Grand Rounds, Egleston Hospital, Atlanta, GA, 3/1999
15. An approach to Anemia in Children-Sense and Sensibility, Frontiers in Pediatric Conference, Emory/Egleston, Atlanta, GA, 3/1999
16. Thrombosis in Nephrotic Syndrome, Pediatric Grand Rounds, Hugh Spalding Children’s Hospital, Atlanta, GA, 4/1999
17. Viral Safety of Plasma Products, Hematology/Pathology Seminar, Medical College of Georgia, Atlanta, GA, 4/1999
18. Thrombosis in Children: Rarely encountered and Infrequently Explored, Pediatric Grand Rounds, Columbus Medical Center, Columbus, GA, 7/1999
19. Advances in Hemophilia Care: From the Talmud to Gene Therapy, Pediatric Grand Rounds, Nemours Clinic, Jacksonville, FL, 8/1999
20. Viral Safety of Plasma Products, Washington University School of Medicine, St. Louis, MO, 10/1999
21. Solvent Detergent Fresh Frozen Plasma: Safety and Efficacy, Transfusion Medicine Grand Rounds, Johns Hopkins Medical Center , Baltimore, MD, 12/1999
22. Hemophilia: An overview, Pediatric Grand Rounds, University of Mississippi, Oxford, MS, 10/2000
23. Hemophilia: Perspectives on a 2000 year old disease, Pediatric Grand Rounds, University of Arkansas, Fayetteville, AR, 1/2001
24. Inhibitors in Hemophilia, Pediatric Grand Rounds, University of Alabama, Birmingham, AB, 2/2001
25. Treatment of Hepatitis C in Hemophilia, Third Annual Pediatric Hematology/Oncology Seminar, University of New Mexico, Albuquerque, NM, 8/2001
26. History of Hemophilia, Penn State Medical Center, Hershey, PA, 12/2001
27. Prophylaxis in Hemophilia, Pediatric Hematology/Oncology Grand Rounds, Visiting Professor, University of Texas Southwestern Medical School, Dallas, TX, 2/2002
28. Viral Safety, Memphis Hemophilia Group, Memphis, TN, 8/2002
29. Autoimmune Hemolytic Anemia, Pediatric Grand Rounds, Hughes Spalding Children’s Hospital, Atlanta, GA, 12/2002
30. History of Hemophilia, University of Pennsylvania Hemophilia Program, Philadelphia, PA, 7/2003
31. Prophylaxis in Hemophilia, Prophylaxis in Hemophilia, Iowa City, IA, 4/2004
32. Approach to Anemia in Children, Grand Rounds, Children's Hospital of Atlanta at Scottish Rite, Atlanta, GA, 5/2004
33. Approach to Mild Bleeding Disorders, Review Course for Practitioners, University of New Mexico, Albuquerque, NM, 8/2004
34. Prophylaxis in Hemophilia, Grand Rounds Children’s Hospital of Philadelphia, Philadelphia, PA, 9/2004
35. Von Willebrand Disease, Grand Rounds, St. Jude Children’s Research Hospital, Memphis, TN, 9/2004
36. Thrombosis in Children, Grand Rounds, Uniformed Service University of the Health Sciences, Washington, DC, 11/2004 - 11/2007
37. Thrombosis in Children, General Pediatric Conference, Hilton Head, SC, 7/2005
38. Thrombocytopenia in Children, General Pediatric Conference, Hilton Head, SC, 7/2005
39. Approach to Anemia, General Pediatric Conference, Hilton Head, SC, 7/2005
40. Approach to the Bleeding Child, General Pediatric Conference, Hilton Head, SC, 7/2005
41. Clinical Trials in Recombinant PFVIII, Winship Cancer Institute Grand Rounds, Atlanta, GA, 5/2006
 
Regional
1. Redionuclide Synovectomy in Hemophilia, Regional IVS Hemophilia Meeting, Orlando, FL, 9/1998
2. Rationale Use of Anticoagulant Therapy, Regional IVS Hemophilia Meeting, Orlando, FL, 9/1998
3. Clinical Trials Update, State Hemophilia Meeting - Annual Presentation, 1998 - 2001
4. Hepatitis C in Hemophilia, Region IVS Hemophilia Meeting, Ft. Lauderdale, FL, 3/2000
5. Hepatitis C: Is there Hope on the Horizon, Illinois Hemophilia Society, Chicago, IL, 10/2000
6. Viral Safety, Regional Hemophilia Meeting, Ft. Lauderdale, FL, 10/2001
7. Prophylaxis and Surgical Intervention in Hemophilia, Virginia Hemophilia Group, University of Virginia, Charlottesville, VA, 11/2001
8. Final results of the National Hepatitis C Trial, State Hemophilia Meeting, 3/2002
9. Reflections on the Pathophysiology and Treatment of Joint Disease, Region IX Hemophilia Meeting, San Diego, CA , 4/2008
 
National
1. Inhibitors in Hemophilia, New Hemophilia Nurse Coordinator Course, Atlanta, GA, 5/1996 - 5/1998
2. Hematology Oncology Issues for the Pediatrician, Annual American Academy of Pediatrics Spring Meeting, Atlanta, GA, 4/1997
3. Prophylaxis in Hemophilia , New Hemophilia Nurse Coordinators Course Presented Yearly, Atlanta, GA, 5/1997 - 5/1999
4. An Overview of Coagulation and Platelet Disorders, Pediatrics Review Course, The Osler Institute, Atlanta, GA, 6/1997
5. Treatment of Hepatitis C in Hemophilia Patients, National Hemophilia Foundation, Hepatitis Symposium, Philadelphia, PA, 3/1998
6. Moderated and presented at two sessions on joint disease, National Hemophilia Foundation Annual Meeting, San Diego, CA, 10/1998
7. Hepatitis C in the Hemophilia Patient, National Hemophilia Foundation Annual Meeting, Orlando, FL, 10/1998
8. Overview of Coagulation and Platelet Disorders; White and Red Blood Cell Disorders, Pediatrics Osler Review Course, Yearly, 1998 - 2001
9. An Approach to Common Hematology Problems in the Outpatient Setting: Sense and Sensibility, American Academy of Pediatric Annual Meeting Moderator and Speaker, Washington, DC, 10/1999
10. Moderated and presented at two sessions on joint disease, National Hemophilia Foundation Annual Meeting, Orlando, FL, 11/1999
11. Hepatitis C in Hemophilia, National Hemophilia Foundation, Milwaukee, WI, 5/2000
12. Moderator of VWD and Hemophilia Symposium, Annual Meeting of American Society of Pediatric Hematology Oncology, Minneapolis, MN, 9/2000
13. Inhibitors in Hemophilia, Advanced Hemophilia Nurse Course Meeting, Boston, MA, 9/2000
14. Use of rFVII in Newborns, National Consensus Meeting Sponsored by NovoNordisk, 11/2000
15. Hepatitis C in Hemophilia - Is There Hope on the Horizon?, National Hemophilia Annual Meeting, Los Angeles, CA, 11/2000
16. Prophylaxis in Hemophilia, American Society of Hematology Annual Meeting - Aventis Sponsored Symposium, Sand Francisco, CA, 12/2000
17. Second Generation rFVIII in Hemophilia, National Teleconference Sponsored by Bayer, 4/2001
18. Prophylaxis in Hemophilia, American Society of Pediatric Hematology Oncology - Wyeth Sponsored Symposium, Baltimore, MD, 4/2001
19. Recombinant Therapy: Enhancing Safety and Quality of Life, National Hemophilia Foundation Meeting, Wyeth Sponsored Symposium Moderator and Speaker, Nashville, TN, 11/2001
20. Inhibitors in Hemophilia, Advanced Hemophilia Nurse Course Meeting, Boston, MA, 4/2002
21. Persistent Problems in Hemophilia, American Society of Pediatric Hematology/Oncology Annual Meeting, Baltimore, MD, 5/2002
22. Hemophilia and vWD, Comprehensive Pediatric Hematology Board Review Course Sponsored by the American Society for Pediatric Hematology Oncology, Chicago, IL, 9/2002
23. Overview of Coagulation and Acquired/Rare Hemostatic Disorders, Comprehensive Pediatric Hematology Board Review Course Sponsored by the American Society for Pediatric Hematology Oncology, Chicago, IL, 9/2002
24. The Inhibitor Challenge: Bench to Bedside, American Society of Pediatric Hematology Oncology Corporate Friday Symposium, Aventis Sponsored, American Society of Hematology Annual Meeting, Co-Moderator, Philadelphia, PA, 12/2002
25. Joint Disease in VWD, National Hemophilia Foundation Annual Meeting, Salt Lake City, UT, 11/2003
26. Inhibitors in Hemophilia, New Hemophilia Nurses Program, Atlanta, GA, 5/2004
27. Overview of Hemophilia, New Hemophilia Nurses Program, Atlanta, GA, 5/2004
28. Overview of Hemostasis and Rare/Acquired Coagulation Disorders, American Society of Pediatric Hematology Oncology Review Course, Chicago, IL, 10/2004
29. Von Willebrand Disease: Overview and Treatment, National Hemophilia Foundation Annual Meeting, Atlanta, GA, 11/2004
30. Hemophilia, American Society of Hematology (ASH) Annual Meeting, “Meet the Professor” Session, San Diego, CA, 12/2004
31. Controversies in rFVIII Treatment, American Society of Hematology, ZIB Behring Invited Event, San Diego, CA, 12/2004
32. Overview and Challenges in Diagnosis and Treatment of VWD, ZLB Sponsored Teleconference, 3/2005
33. rFVIII in the Treatment of Hemophilia A, HTRS Annual Meeting, Chicago, IL, 4/2005
34. Prophylaxis and Joint Disease in Hemophilia, American Society of Pediatric Hematology Oncology Annual Meeting, Washington, DC, 5/2005
35. Overview of Hemophilia, New Hemophilia Nurse Coordinator Workshop, Atlanta, GA, 5/2005
36. Challenges of Post-Licensure Data Collection, FDA Meeting, Washington, DC, 6/2005
37. The National Database, National Hemophilia Foundation, San Diego, CA, 10/2005
38. Hemophilia-A Clinical Overview, New Nurse Coordinator Workshop, Atlanta, GA, 4/2006
39. Overview of Coagulation, American Society of Pediatric Hematology Review Council, Chicago, IL, 10/2006
40. Women with Bleeding Disorders, National Hemophilia Foundation (NHF) on the Road, New Orleans, LA, 4/2007
41. Hemophilia-A Clinical Overview, New Nurse Coordinator Workshop, Atlanta, GA, 4/2007
42. Prophylaxis in Bleeding Disorders and Diagnosis of vWD, American Society of Pediatric Hematology/Oncology (ASPHO), Toronto, Ontario, Canada, 5/2007
43. Diagnosis and Treatment of vWD, National Hemophilia Foundation (NHF) Annual Meeting, Orlando, FL, 11/2007
44. vWD Prophylaxis, National Hemophilia Foundation (NHF) Annual Meeting, Orlando, FL, 11/2007
45. Overview of Hemophilia, New Hemophilia Nurse Coordinator Workshop, Atlanta, GA , 4/2008
46. Research Practices and Approaches, American Thrombosis and Hemostasis Network (ATHN), Chicago, IL, 7/2008
47. Training in Benign Hematology , American Society of Hematology Program Director Workshop, San Francisco, CA, 12/2008
48. Hemophilia and VWD, American Society of Pediatric Hematology Oncology (ASPHO) Review Course, Dallas, TX, 2/2009
49. Mentoring and Career Development, American Society of Pediatric Hematology Oncology (ASPHO) Fellowship Program Directors Annual Meeting , San Diego, CA, 4/2009
50. Treatment of VWD, American Society of Pediatric Hematology Oncology (ASPHO) Annual Meeting, San Diego, CA, 4/2009
51. Overview of vWD, New Hemophilia Nurse Coordinator Workshop, Atlanta, GA, 4/2009
52. The Road Less Traveled-Careers in Hematology, American Society of Hematology (ASH) Annual Meeting, Orlando, FL, 12/2010
53. The Anemia of Inflammation, Ogden Bruton Lectureship, Uniformed Services Pediatric Seminar, Washington, DC, 3/2011
 
International
1. Treatment of relapsed ALL using PEG-asparaginase, International Asparaginase and Leukemia Symposium, Los Angeles, CA, 1/1998
2. Central Lines and Thrombosis, Perinatal Subcommittee, International Congress on Thrombosis and Hemostasis, Washington, DC, 8/1999
3. Treatment of Hepatitis C in Hemophilia, International Hemophilia Meeting sponsored by Bayer, Madrid, Spain, 9/1999
4. An Approach to the Diagnosis and Treatment of Bleeding Disorders in Children, Education Symposium (Benign Hematology), International Society of Hematology Annual Meeting, Seoul, South Korea, 8/2002
5. Overview of Plasma and Recombinant FVIII Therapies, World Federation of Hemophilia, Bangkok, Thailand, 10/2004
6. Prophylaxis and Joint Disease in Hemophilia A, International Society of Thrombosis and Hemostasis (ISTH) SSC Meeting, Sydney, Australia, 8/2005
7. Current Treatment Strategies for Hemophilia B, International Society of Thrombosis and Hemostasis (ISTH) SSC Meeting, Sydney, Australia, 8/2005
8. The Von Willebrand Disease Prophylaxis Network, International Society of Thrombosis and Hemostasis (ISTH) SSC Meeting, Sydney, Australia, 8/2005
9. Prophylaxis and VWD, International Society of Thrombosis and Hemostasis (ISTH) SSC Meeting, Sydney, Australia, 8/2005
10. Recombinant Porcine FVIII, World Federation of Haemophilia, Vancouver, BC, 5/2006
11. Hemophilia B Treatment, World Federation of Haemophilia, Vancouver, BC, 5/2006
12. vWD Prophylaxis, International Society of Thrombosis and Hemostasis (ISTH) SSC Meeting, Oslo, Norway, 6/2006
13. Prophylaxis in vWD, International Society of Thrombosis and Hemostasis (ISTH), Geneva, Switzerland, 5/2007
14. Von Willebrand Disease Prophylaxis Network, European Association for Haemophilia and Allied Disorders, Amsterdam, The Netherlands, 2/2008
15. VWD Prophylaxis Network, World Federation of Hemophilia Meeting, Istanbul, Turkey, 6/2008
16. Prophylaxis in vWD, International Society of Thrombosis and Hemostasis (ISTH) SSC Meeting, Vienna, Austria, 7/2008
17. Role of Prophylaxis in the Management of VWD, International Society of Thrombosis and Hemostasis (ISTH) Biannual Meeting Symposium, Boston, MA, 7/2009
18. American Thrombosis and Hemostasis Network Database, European Association for Haemophilia and Allied Disorders, Edinburgh, UK, 2/2010
19. Evaluation for Bleeding Disorders when Child Abuse is Suspected, Eleventh International Conference on Abusive Head Trauma, Atlanta, GA, 9/2010
20. The clinical and laboratory diagnosis of VWD, 57th Annual Meeting of the Scientific and Standardization Committee and Education Sessions, Kyoto, Japan, 7/2011
 
PEER REVIEWED WORKSHOPS/PRESENTATIONS:
National
1. Creary M, Soucie JM, Miller CH, Hooper WC, Abshire TC, Brettler DB, Pokenstedt PL, DiPaola JA, Massey G, Neff A, Shapiro A, Tarantino M, Wicklund BM, DiMichele D, U.S. Inhibitor Pilot Project: Participant Characteristics and Infusion Log Adherence, American Society of Hematology (ASH) 37th Annual Meeting, Atlanta, GA, 12/1997
2. Howard T, Machiah DM, Tran TT, Viel KR, Channell C, Soria JM, Ameri A, Iyer RV, Brown C, Doering C, Almasy L, Watts R, Davis J, Abshire TC, African-Americans Express Multiple Haplotypic Forms of the Wildtype Factor VIII (FVIII) Protein: A Possible Role for Pharmacogenetics in FVIII Inhibitor Development?, American Society of Hematology (ASH) 34th Annual Meeting - Plenary Session, San Diego, CA, 12/2004
3. Bennett CM, Bussel JB, Mueller BU, Abshire TC, Sawaf H, Moore TB, Loh ML, Rogers ZR, Feldman HA, Neufeld EJ, the Glaser Pediatric Research Network for The Pediatric ITP/Rituximab Study Group, Pharmacokinetics (PK) substudy of rituximab in a prospective clinical trial for pediatric chronic immune thrombocytopenic purpura (cITP), American Society of Hematology (ASH) 47th Annual Meeting - Poster Session, Atlanta, GA, 12/2005
4. Howard TE, Machiah DK, Viel KR, Channel C, Ameri A, Iyer RV, Watts RG, Lutcher C, Davis J, Abshire TC, Almasy L, The pharmacogenetics and inhibitor risk (PIR) study: establishing the spectrum of factor (F)VIII gene (F8) mutations in African-American hemophilia a patients, American Society of Hematology (ASH) 47th Annual Meeting - Poster Session, Atlanta, GA, 12/2005
5. Manco-Johnson MJ, Abshire TC, Brown D, Buchanan GR, Cohen AR, DiMichele D, Hoots WK, Leissinger C, McRedmond K, Nugent DJ, Shapiro AD, Thomas GA, Valentino LA, Riske B, Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency, American Society of Hematology (ASH) 47th Annual Meeting - Plenary Session, Atlanta, GA, 12/2005
6. Eapen M, Raetz E, Zhang MJ, Muehlenbein C, Devidas M, Abshire T, Billett A, Homans A, Camitta B, Carroll W, Davies S, Outcomes after HLA-matched sibling transplants or chemotherapy in children with acute lymphoblastic leukemia in second remission: A collaborative study of the Children’s Oncology Group (COG) and the Center for International Blood and Marrow Transplant Research (CIBMTR), American Society of Hematology (ASH) 47th Annual Meeting - Oral Session, Atlanta, GA, 12/2005
7. Shapiro A, Abshire T, Hernandez F, Gruppo R, Tarantino M, Warrier I, Schroth P, Spotts G, Retzios A, Ewenstein B, Efficacy and safety of ADVATE rAHF-PFM for perioperative management of hemostasis in previously treated children with hemophilia A, XXVII World Federation of Hemophilia's (WFH) World Hemophilia Congress - Poster Session, Vancouver, Canada, 5/2006
8. Howard TE, Viel KR, Fernstrom KM, Deshpande S, Ameri A, Ali MS, Channell C, Iyer RV, Watts RG, Lutcher C, Nakaya S, Kasper CK, Thompson AR, Abshire TC, Almasy L, Allelically Mismatched Replacement Therapy Due to Common African-Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia-A Patients of African-Descent, American Society of Hematology (ASH) 35th Annual Meeting, Atlanta, GA, 12/2006
9. Howard TE, Viel KR, Fernstrom KM, Deshpande S, Ameri A, Ali MS, Channell C, Iyer RV, Watts RG, Lutcher C, Nakaya S, Kasper CK, Thompson AR, Abshire TC, Almasy L, Allelically Mismatched Replacement Therapy Due to Common African–Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia–A Patients of African–Descent, American Society of Hematology (ASH) 36th Annual Meeting - Oral Session, Orlando, FL, 12/2006
10. Haberichter SL, Christopherson PA, Perry CL, Lee A, Morateck PA, Bellissimo DB, Gill JC, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro Ad, Montgomery RR, The Prevalence of Reduced VWF Survival Phenotype (Type 1C VWD) in Type 1 Index Cases Recruited into the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB - VWD), American Society of Hematology (ASH) 37th Annual Meeting - Poster Session, Atlanta, GA, 12/2007
11. Miller CH, Platt SJ, Abshire T, Brettler D, Brokenstedt P, DiPaola J, Massey G, Neff A, Shapiro A, Tarantino M, Wicklund B, Creary M, Soucie MJ, Experience with a Modified Nijmegen-Bethesda Method for Measurement of Inhibitors in Hemophilia Patients: The CDC Inhibitor Surveillance Pilot Project, American Society of Hematology (ASH) 37th Annual Meeting - Poster Session, Atlanta, GA, 12/2007
12. Bellissimo DB, Christopherson PA, Haberichter SL, Flood VH, Gill JC, Friedman KD, Abshire TC, DiPaola, Hoots WK, Leissinger C, Lusher JM, Ragni AD, Shapiro AD, Montgomery RR, Novel VWF Sequence Variations Identified in Normal Controls and Index Cases Enrolled in the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB-VWD), American Society of Hematology (ASH) 37th Annual Meeting - Oral Session, Atlanta, GA, 12/2007
13. Flood VH, Kautza BC, Miller CA, Branchford BR, Gill JC, Haberichter SL, Morateck PA, Christopherson PA, Perry CL, Friedman KD, Bellissimo DB, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro A, Lillicrap D, Goodeve AC, Peake IR, Montgomery RR, Common VWF Haplotypes in Normal African-Americans and Caucasians Recruited into the ZPMCB-VWD and Their Impact on VWF Laboratory Testing, American Society of Hematology (ASH) 37th Annual Meeting - Oral Session, Atlanta, GA, 12/2007
14. Miller CH, Hooper C, Abshire TC, Bockenstedt PL, Brettler DB, Di Poala J, Massey G, Neff AT, Shapiro AD, Tarantino M, Wicklund BM, Manco-Johnson MJ, Dunn AL, Knoll C, Creary M, Benson J, Ellingsen D, Driggers J, Soucie JM, Factor VIII and Factor IX Mutation Analysis in 600 U.S. Hemophilia Patients: Correlation of Mutation Type with History of Inhibitor, American Society of Hematology (ASH) 38th Annual Meeting - Poster Session, San Francisco, CA, 12/2008
15. Kempton CL, Soucie JM, Miller CH, Hooper C, Escobar MA, Reding MT, Cohen AJ, Key NS, Thompson AR, Manco-Johnson MJ, Abshire TC, Risk Factors for Inhibitor Development in Mild and Moderate Hemophilia A: A Case-Control Study, American Society of Hematology (ASH) 39th Annual Meeting - Poster Session, New Orleans, LA, 12/2009
16. Berntorp E, Abshire TC, Federici AB, Regular Replacement Therapy as Prophylaxis In Severe Forms of Von Willebrand Disease: Initial Results From the Von Willebrand Disease Prophylaxis Network (VWD PN) Study Group, American Society of Hematology (ASH) 40th Annual Meeting - Oral Session, Orlando, FL, 12/2010
 
International
1. Miller CH, Nix B, Benson E, Abshire TC, Platelet aggregation and ATP release in whole blood for diagnosis of bleeding disorders, XIX International Society on Thrombosis & Haemostasis (ISTH) Congress & 49th Annual Standardization Committee (SSC) Meeting - Symposium, Birmingham, England, 7/2003
2. Abshire TC, Use of prophylaxis as routine management and surgical cover for patients with haemophilia, XIX International Society on Thrombosis & Haemostasis (ISTH) Congress & 49th Annual Standardization Committee (SSC) Meeting - Symposium, Birmingham, England, 7/2003
3. Dunn A, Abshire T, Balark K, Manco-Johnson M, Leukemia after P32 Radionuclide Synovectomy for Hemophilic Arthropathy, XX International Society on Thrombosis & Haemostasis (ISTH) Congress & 51st Annual Standardization Committee (SSC) Meeting - Poster Session, Sydney, Australia, 8/2005
4. Machiah DK, Howard T, Tran TT, Viel KR, Channell C, Soria JM, Ameri A, Iyer RV, Brown C, Doering C, Almawsy L, Watts R, Davis J, Abshire TC, The pharmacogenetics and inhibitor risk study: No significant differences found in the mutational spectrum of African-Americans with Hemophilia A, XX International Society on Thrombosis & Haemostasis (ISTH) Congress & 51st Annual Standardization Committee (SSC) Meeting, Sydney, Australia, 8/2005
5. Brandao L, Briones M, Miller CH, White JG, Kauffman J, Abshire TC, Clinical and laboratory features of mild bleeding disorders, XX International Society on Thrombosis & Haemostasis (ISTH) Congress & 51st Annual Standardization Committee (SSC) Meeting - Poster Session, Sydney, Australia, 8/2005
6. Manco-Johnson MJ, Abshire TC, Brown D, Buchanan GR, Cohen AR, DiMichele D, Hoots K, Leissinger C, McRedmond K, Nugent DJ, Shapiro AD, Thomas GA, Valentino LA, Riske B, Randomized, controlled, multi-year study to evaluate joint outcomes in young children using recombinant factor VIII (Kogenate FS), XXVII World Federation of Hemophilia's (WFH) World Hemophilia Congress - Poster Session, Vancouver, Canada, 5/2006
7. Abshire T, Hoots K, Kessler C, MacFarlane D, Gergman G, Preclinical and clinical experiences with a recombinant porcine FVIII product, XXVII World Federation of Hemophilia's (WFH) World Hemophilia Congress, Vancouver, Canada, 5/2006
8. Berntorp E, Abshire T, Carcao M, DiPaola J, Donfield S, Gill J, Kouides P, Kurnik K, Leebeek F, Lethagen S, Makris M, Mannucci P, Mathew P, Suiter T, Winikoff R, An international endeavor to define and evaluate regimens for prophylaxis in vWD, XXVII World Federation of Hemophilia's (WFH) World Hemophilia Congress, Vancouver, Canada, 5/2006
9. Soucie M, Kulkarni R, Abshire T, Hoots W, Curtis R, Drake J, Duffy N, Forsyth A, Key N, Konkle B, Kuebler E, Nielsen B, Hemophilia and inherited bleeding disorders in the first 2 years of life: diagnosis, mode of delivery and bleeding sites – a report from the baby Universal Data Collection (UDC) surveillance project of the Centers for Disease Control and Prevention, XXVII World Federation of Hemophilia's (WFH) World Hemophilia Congress, Vancouver, Canada, 5/2006
10. Hay, CRM, Keegan J, Goldstone J, Hirsch S, Ewing N, Abshire T, DiMichele DM, for the International ITI Study Group, International immune tolerance (ITI) study: frequency of central venous line infection and effect on ITI outcome, XXVII World Federation of Hemophilia's (WFH) World Hemophilia Congress - Poster Session, Vancouver, Canada, 5/2006
11. Ashrani A, Key N, Duffy N, Forsyth A, Geraghty S, Abshire T, Curtis R, Drake J, Hoots W, Kuebler E, Konkle B, Kulkarni R, Nielsen B, Soucie J, Characteristics of and risk factors for septic arthritis in males with hemophilia, XXVII World Federation of Hemophilia's (WFH) World Hemophilia Congress, Vancouver, Canada, 5/2006
12. Soucie JM, Miller CH, Creary M, Hooper WC, Abshire TC, Brettler DB, Bockenstedt P, Dipoala J, Massey G, Neff A, Shapiro A, Tarantino M, Wicklund BM, DiMichele D, UDC Working Group, U.S. Inhibitor Pilot Project: Study Design and Methods Validation, XXI International Society on Thrombosis & Haemostasis (ISTH) Congress & 53rd Annual Standardization Committee (SSC) Meeting, Geneva, Switzerland, 8/2007
13. Markris M, Federici, Yee T, Abshire TC, Berntorp E, Mannucci PM, The Diagnosis and Management of Von Willebrand Disease (VWD) Associated Angiodysplasia, XXIII International Society on Thrombosis & Haemostasis (ISTH) Congress & 57th Annual Scientific & Standardization Committee (SSC) Meeting - Poster Session, Kyoto, Japan, 7/2011
 
COMMITTEE SERVICE:
Medical College
2010 - 2011 Member, Division Chief Search Committee, Hematology/Oncology/BMT, Pediatrics, Medical College of Wisconsin
 
MEDICAL COLLEGE TEACHING ACTIVITIES:
Resident and Fellow Education
2010 - Present Outpatient clinic attending 1/2 day per week
2010 - Present Inpatient hematology ward attending with daily teaching rounds 4 weeks/year
 
EXTRAMURAL TEACHING (e.g. at Marquette, UWM, etc.):
Medical Student Education
1995 - 2002 Emory University School of Medicine, Core pediatrics rotation, meet weekly (1 ½ -2 hrs) for one 6 week rotation/year and 1-2 oral exam sessions/year (4 hrs/session)
1996 - 2005 Emory University School of Medicine, Education Coordinator (residents and medical students), Division of Pediatric Hematology/Oncology. Curriculum/orientation for all rotating residents (2-4 residents monthly) and medical students.
 
Resident and Fellow Education
1995 - 2009 Emory University School of Medicine, Inpatient ward attending with daily teaching rounds 6 weeks and clinic exposure to fellows, residents, and medical students 1-1/2 days per week when not attending.
1996 - 2008 Emory University School of Medicine, Pediatric Hematology/Oncology Fellowship Program: Supervision of fellows on inpatient ward (1-2 months/yr and outpatient clinic (1-2 days/week); weekly textbook and weekly slide review (1 1/2 hrs/wk).
2001 - 2008 Emory University School of Medicine, Facilitator, Division hematology case, presented by Hematology/Oncology fellows.
2001 - 2008 Emory University School of Medicine, Facilitator, Division Hematology Case Presentations
 
Continuing Medical Education
1999 - 2002 Emory University School of Medicine, Facilitator of Emory/CDC/Children’s Coagulation Conference (3x/mos, Sep-May of each year).
 
MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:
Faculty
Veronica Flood, MD, Medical College of Wisconsin, 2010 - Present
 
EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:
Clinical/Research Fellows
Amy Dunn, MD, Emory University, 1998 - 2005
Glen Lew, MD, Emory University, 1999 - 2002
 
Residents
Uta Rokahr, Emory University, 1996 - 1999
Claude Ashley, Emory University, 1996 - 1998
David Kotzbauer, Emory University, 1999 - 2001
Leo Brandao, Emory University, 2000 - 2002
Leslie Kean, Emory University, 2000 - 2005
Michael Whitcamp, Emory University, 2001 - 2003
 
Faculty
Mike Briones, DO, Emory University, 2000 - 2009
Jeanne Hendrickson, MD, Emory University, 2002 - 2007
Shannon Meeks, MD, Emory University, 2004 - 2009
Christine Kempton, MD, Emory University, 2005 - 2009
Carolyn Bennett, MD, Emory University, 2007 - 2009
Anand Padmanabhan, MBBS, PhD, Blood Research Institute, 2010 - Present
Joshua Field, MD, MS, Blood Research Institute, 2010 - Present
 
NATIONAL ADVISORY BOARDS:
1999 - 2007 Bayer
1999 - 2009 Novo Nordisk
1999 CDC
1999 - Present Aventis/ ZLB Behring/ CSL Behring
1999 - 2000 American Red Cross
1999 - 2005 Wyeth
2001 - 2004 Baxter
2009 Bayer


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Abshire TC, Reeves JD. Anemia of acute inflammation in children. J Pediatr. 1983 Dec;103(6):868-71.
2. Abshire TC, English JL, Githens JH, Hambidge M. Zinc status in children and young adults with sickle cell disease. Am J Dis Child. 1988 Dec;142(12):1356-9.
3. Abshire TC, Gold S, Odom LF, Carson SD, Hathaway WE. The coagulopathy of childhood leukemia. Thrombin activation or primary fibrinolysis? Cancer. 1990 Aug 15;66(4):716-21.
4. Manco-Johnson MJ, Abshire TC, Jacobsen LJ, Marlar RA. Severe neonatal protein C deficiency: prevalence and thrombotic risk. J Pediatr. 1991 Nov;119(5):793-8.
5. Abshire TC, Buchanan GR, Jackson JF, Schuster JJ, Brock B, Head D, Behm F, Crist WM, Link M, Borowitz, Pullen DJ. Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study. Leukemia. 1992 May;6(5):357-62.
6. Werner EJ, Abshire TC, Giroux DS, Tucker EL, Broxson EH. Relative value of diagnostic studies for von Willebrand disease. J Pediatr. 1992 Jul;121(1):34-8.
7. Seltzer WK, Abshire TC, Lane PA, Roloff JS, Githens JH. Molecular genetic studies in black families with sickle cell anemia and unusually high levels of fetal hemoglobin. Hemoglobin. 1992;16(5): 363-377.
8. Shea MP, Abshire TC. Philadelphia chromosome-positive chronic myeloid leukemia and thoracic ganglioneuroma. Previously undescribed association. Am J Pediatr Hematol Oncol. 1993 Feb;15(1):111-4.
9. Berdeaux DH, Abshire TC, Marlar RA. Dysfunctional protein C deficiency (type II). A report of 11 cases in 3 American families and review of the literature. Am J Clin Pathol. 1993 Jun;99(6):677-86.
10. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993 Dec;123(6):893-8.
11. Abshire TC, Fink LK, Christian J, Hathaway WE. The prolonged thrombin time of nephrotic syndrome. J Pediatr Hematol Oncol. 1995 May;17(2):156-62.
12. Bartholomew D, Abshire T, Fries M, Smith A. Novel missense mutation in the coagulation factor IX catalytic domain associated with moderate disease. Hum Mutat. 1997;9(1):72-3.
13. Bernstein ML, Abshire TC, Pollock BH, Devine S, Toledano S, Steuber CP, Bowman WP, Buchanan GR. Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):68-72.
14. Hymel KP, Abshire TC, Luckey DW, Jenny C. Coagulopathy in pediatric abusive head trauma. Pediatrics. 1997 Mar;99(3):371-5.
15. Tomer A, Masalunga C, Abshire TC. Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation. Am J Hematol. 1999 May;61(1):53-61.
16. Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia. 2000 Jan;6(1):11-4.
17. Zhou M, Gu L, Abshire TC, Homans A, Billett AL, Yeager AM, Findley HW. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia. 2000 Jan;14(1):61-7.
18. Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. Thromb Haemost. 2000 Jun;83(6):811-6.
19. Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood. 2000 Sep 1;96(5):1709-15.
20. Scharrer I, Brackmann HH, Sultan Y, Abshire T, Gazengel C, Ragni M, Gorina E, Vosburgh E, Kellermann E. Efficacy of a sucrose-formulated recombinant factor VIII in 22 surgical procedures in patients suffering from severe haemophilia A. Haemophilia. 2000;6(6):614-618.
21. Forte K, Abshire T. The use of hepzyme in removing heparin from blood samples drawn from central venous access devices. J Pediatr Oncol Nurs. 2000;17(3):179-181.
22. Dunn AL, Busch MT, Wyly JB, Abshire TC. Radionuclide synovectomy for hemophilic arthropathy: a comprehensive review of safety and efficacy and recommendation for a standardized treatment protocol. Thromb Haemost. 2002 Mar;87(3):383-93.
23. Male C, Chait P, Ginsberg JS, Hanna K, Andrew M, Halton J, Anderson R, McCusker P, Wu J, Abshire T, Cherrick I, Mahoney D, Mitchell L. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study, Thromb Haemost. 2002;87(4):593-598.
24. Fried MW, Peter J, Hoots K, Gaglio P, Talbut D, Mathew P, Davis PC, Key N, White GC, Lindblad L, Rickles F, Abshire TC. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology. 2002 Oct;36(4 Pt 1):967-72.
25. Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, Cherrick I, Desai S, Mahoney D, McCusker P, Wu J, Dahl G, Chait P, deVeber G, Kyong-Jin L, Mikulis D, Ginsberg J, Way C. A prospective cohort study determining the prevalence of thrombotic events in children with acute Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Treated with Asparaginase (PARKAA) Study. Cancer. 2003;97(2):508-16.
26. Young G, Manco-Johnson M, Gill JC, DiMichele D, Tarantino M, Abshire T, Nugent D. Clinical manifestations of the prothrombin G20210 mutation in children: a pediatric coagulation consortium study. J Thromb Hemost. 2003;1(5):958-62.
27. Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J, Anderson I, Cherrick I, Desai S, Mahoney D, McCusker P, Chait P, Abdolell M, de Veber G, Mikulis D. Trend to Efficacy and Safety Using Antithrombin Concentrate in Prevention of Thrombosis in Children Receiving L-Asparaginase for Acute Lymphoblastic Leukemia: Results of the PARKAA Study. Thromb Haemost, 2003;90(2):235-44.
28. Abshire TC, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with hemophilia and FVIII or FIX inhibitors or acquired inhibitors. J Thromb Haemost. 2004;2(6):899-909.
29. Soucie JM, Cianfrini C, Janco RL, Kulkarni R, Hambleton J, Evatt B, Forsyth A, Geraghty S, Hoots K, Abshire T, Curtis R, Forsberg A, Huszti H, Wagner M, White II GC. Joint Range of Motion Limitations Among Young Males with Hemophilia: Prevalence and Risk Factors. Blood. 2004;103(7):2467-73.
30. Dunn AL, Busch M, Wyly JB, Sullivan K, Peter J, Abshire TC. Arthroscopic synovectomy for hemophilic joint disease in a pediatric population. J Pediatr Orthop. 2004 Jul-Aug;24(4):414-26.
31. Bussel JB, Eldor A, Kelton JG, Varon D, Brenner B, Gillis S, Angiolillo A, Kulkarni R, Abshire TC, Kelleher J and the IGIV-C in ITP Study Group. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost. 2004 Apr;91(4):771-8.
32. Dunn AL, Manco-Johnson M, Busch MT, Balark KL, Abshire TC. Recent advances in the management of the child who has hemophilia. Hematol Oncol Clin North Am. 2004 Dec;18(6):1249-76, viii.
33. Shapiro AD, DiPaola J, Cohen A, Pasi J, Heisel MA, Blanchette VS, Abshire TC, Hoots WK, Lusher JM, Negrier C, Rothschild C, Roth DA. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood. 2005 Jan 15;105(2):518-25.
34. deAlarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, Abshire T, Hambleton J, Matthew P, Ortiz I, Cohen A, Konkle BA, Streiff M, Lee M, Wages D, Corash L. Fresh frozen plasma prepared with amotosalen HCI (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion. 2005;45(8):1362-72.
35. Dunn AL, Manco-Johnson M, Busch MT, Balark KL, Abshire TC. Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy. J Thromb Haemost. 2005 Jul;3(7):1541-2.
36. Eapen M, Raetze, Zhang MJ, Muehlenbein C, Devidas M, Abshire T, Billett A, Homans A, Camitta B, Carroll WL and Davies SM for the Children’s Oncology Group and the Center for International Blood and Marrow Transplant Research. Outcomes after HLA-matches sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children’s Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood. 2006 June;107:4961-4967.
37. Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006 Apr 1;107(7):2639-42.
38. Kuhle S, Lau A, Bajzar L, Vegh P, Halton J, Cherrick I, Anderson R, Desai S, McCusker P, Wu J, Abshire T, Mahoney D, Mitchell L. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study. Br J Haematol. 2006 Sep;134(5):526-31.
39. Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost. 2006 Dec;4(12):2576-81.
40. Berntorp E, Abshire T. von Willebrand Disease Prophylaxis Network Steering Committee. The von Willebrand disease prophylaxis network: exploring a treatment concept. J Thromb Haemost. 2006 Nov;4(11):2511-2.
41. Mannucci PM, Abshire T, Dimichele D, Santagostino E, Blanchette V. Inhibitor development , immune tolerance and prophylaxis in haemophilia A—the need for an evidence-based approach. Haemophilia. 2006 Jul;12(4):429-34.
42. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Funk S, Jacobson L, Valentino LA, Hoots WD, Buchanan GR, DiMichele D, Recht M, Brown D, Leissenger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007 Aug 9;357(6):535-44.
43. Hastings C, Wechsler DS, Stine KC, Graham DK, Abshire T. Consensus on a core curriculum in American training programs in pediatric hematology-oncology: a report from the ASPHO Training Committee. Pediatr Hematol Oncol. 2007 Oct-Nov;24(7):503-12.
44. Dunn AL, Abshire TC. Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy. Pediatr Blood Cancer. 2008 Mar;50(3):627-9.
45. Abshire TC, Genet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or XI with inhibitors. Haemophilia. 2008 Sep;14:898-902.
46. Meeks SL, Abshire TC. Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment. Haemophilia. 2008 Nov;14(6):1159-63.
47. Veil KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C, Channell C, Cole SA, Fernstrom KM, Nakaya S, Kasper CK, Thompson AR, Almasy L, Howard TE. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med. 2009 Apr 16;360(16):1618-27.
48. Recht M, Nemes L, Matysiak M, Manco-Johnson M, Lusher J, Smith M, Mannucci P, Hay C, Abshire T, O’Brien A, Hayward B, Udata C, Roth DA, Arkin S. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia. 2009 Jul 15 (4): 869-80.
49. Mueller BU, Bennett CM, Feldman HA, Bussel JB, Abshire TC, Moore TB, Sawaf H, Loh ML, Rogers ZR, Glader BE, McCarthy MC, Mahoney DH, Olson TA, Feig SA, Lorenzana AN, Mentzer WC, Buchanan GR, Neufeld EJ. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatr Blood Cancer. 2009 Feb;52(2):259-62.
50. Kulkarni R, Souci JM, Lusher J, Presley R, Shapiro A, Gill J, Manco-Johnson M, Koerper M, Mathew P, Abshire T, Dimichele D, Hoots K, Janco R, Nugent D, Geraghty S, Evatt B; the Haemophilia Treatment Center Network Investigators. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention’s (CDC) Universal Data Collection (UDC) project. Haemophilia. 2009 Nov;15(6):1281-90.
51. Goldenberg NA, Tripputi M, Crowther M, Abshire TC, Dimichele D, Manco-Johnson MJ, Hiawtt WR. The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. Contemp Clin Trials. 2010 Jan;31(1):131-3.
52. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010 Jul 15;116(2):280-6.
53. Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, Neunert C, Lillicrap D; on behalf of the ISTH/SSC Joint VWF and Perinatal/Pediatric Hemostatsis Subcommitteees Working Group. ISTH/SSC Bleeding Assessment Tool: A Standardized Questionnaire and a Proposal for a New Bleeding Score for Inherited Bleeding Disorders. J Thromb Haemost. 2010 Sep;8(9):2063-5.
54. Kempton CL, Soucie JM, Miller CH, Hooper C, Escobar MA, Cohen AJ, Key NS, Thompson AR, Abshire TC. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost. 2010 Oct;8(10):2224-31.
55. Kempton CL, Meeks SL, Donald Harvey R 3rd, Abshire TC. Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII. Haemophilia. 2011 Jan;17(1):155-6.
56. Abshire T. Unraveling hemophilic arthropathy. Blood. 2011 Feb 24;117(8):2302-3.
57. Aschman DJ, Abshire TC, Shapiro AD, Lusher JM, Forsberg AD, Kulkarni R. A community-based partnership to promote information infrastructure for bleeding disorders. Am J Prev Med. 2011 Dec;41(6 Suppl 4):S332-7.
58. Hay CR, DiMichele DM, International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012 Feb 9;119(6):1335-44.
59. Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, Shapiro AD, Abshire TC, Leissinger C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood. 2012 Mar 1;119(9):2135-40.
60. Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, Manco-Johnson MJ, Monahan PE, Joint Outcome Study Investigators. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther. 2012 Mar;19(3):288-94.
61. Kempton CL, Abshire TC, Deveras RA, Hoots WK, Gill JC, Kessler CM, Key NS, Konkle BA, Kuriakose P, Macfarlane DE, Bergman G. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia. 2012 Apr 19:
62. Abshire T TAFI made stickier. Blood. 2012 Apr 12;119(15):3380-1
63. Anderst JD, Carpenter SL, Abshire TC, Section on Hematology/Oncology and Committee on Child Abuse and Neglect of the American Academy of Pediatrics Evaluation for bleeding disorders in suspected child abuse. Pediatrics. 2013 Apr;131(4):e1314-22
64. Carpenter SL, Abshire TC, Anderst JD, Section on Hematology/Oncology and Committee on Child Abuse and Neglect of the American Academy of Pediatrics Evaluating for suspected child abuse: conditions that predispose to bleeding. Pediatrics. 2013 Apr;131(4):e1357-73
65. Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. Blood. 2013 May 2;121(18):3742-4
66. Abshire TC, Federici AB, Alvárez MT, Bowen J, Carcao MD, Cox Gill J, Key NS, Kouides PA, Kurnik K, Lail AE, Leebeek FW, Makris M, Mannucci PM, Winikoff R, Berntorp E, VWD PN Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia. 2013 Jan;19(1):76-81
67. Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM, Hemophilia Inhibitor Research Study Investigators Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost. 2012 Jun;10(6):1055-61
68. Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Craig Hooper W, Hemophilia Inhibitor Research Study Investigators F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia. 2012 May;18(3):375-82
69. Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM, Hemophilia Inhibitor Research Study Investigators Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost. 2013 Jul;11(7):1300-9
70. Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT, Haemophilia Inhibitor Research Study Investigators A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia. 2014 Mar;20(2):230-7
 
Books, Chapters, and Reviews
1. Abshire TC. The anemia of inflammation: A common cause of childhood anemia. Pediatr Clinic N Am. 1996;43:623-637.
2. George J, Crowther M, Abshire T. Chapter 14. Hemostasis and Thrombosis. In: Michael E. Williams, Marc J. Kahn, eds. American Society of Hematology Self-Assessment Program. Second Edition. 2005.
3. Briones M, Abshire T. Section XIII, Chapter 13-6. Disorder of coagulation, platelet number and function. In: Fredric D. Burg, Julie R. Ingelfinger, Richard A. Polin, Anne Gershon, eds. Current Pediatric Therapy, 18th ed. Saunders; 2005.
4. Crowther M, Abshire T. Chapter 15. Hemostasis and Thrombosis. Marc J. Kahn, Stephanie A. Gregory, eds. American Society of Hematology Self Assessment Program. Third Edition. Blackwell; 2007.
5. Dunn AL, Abshire TC. Recent advances in the management of the child with hemophilia. Pediatr Clinic N Am. 2004;18(6):1249-76.
6. Abshire TC. Chapters 78, 79, 95, 100, 105 - 108, 129 , 130, 140, 144. In: Christopher D. Hillyer, Beth H. Shaz, James C. Zimring, Thomas C. Abshire, eds. Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. 1st Edition. Elsevier; 2009.
7. Dunn AL, Meeks SL, Abshire TC. Chapter 436. Inherited Bleeding Disorders. In: Rudolph CD, Rudolph A, Lister GE, First L, Gershon A, eds. Rudolph's Pediatrics. 22nd ed. New York: McGraw-Hill; 2011.
8. Di Paola J, Abshire TC. Chapter 14. Pediatric aspects of von Willedbrand disease. In: Augusto B. Federici, Christine A. Lee, Erik E. Berntorp, David Lillicrap, Robert R. Montgomery, eds. Von Willebrand Disease: Basic and Clinical Aspects. Hoboken, NJ:Wiley-Blackwell;2011.
 
Editorials, Letters to Editor, Other
1. Abshire TC. Management of hepatitis C in persons with bleeding disorders: Is there hope on the horizon? Hemaware. 1999;4:14-23.
2. Abshire TC. An approach to anemia in children: Sense and Sensibility, Contemp Pediatr. 2001;18:104-113.
3. Abshire TC. An approach to the diagnosis and treatment of bleeding disorders in infants. Int J Hematol. 2002;76(2): 265-70.
4. Abshire TC. The use of hyaluronidase in the treatment of acute hemophilic hemarthrosis in the "50 years ago in pediatrics" series. J Pediatr. 2003;142(3):340.
5. Briones M and Abshire T. Lupus anticoagulants in children. Curr Opin Hematol. 2003;10: 375-379.
6. Abshire T. An approach to target joint bleeding in hemophilia: prophylaxis for all or individualized treatment? J Pediatr. 2004;145(5):581-3.
7. Abshire TC. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing. Semin Hematol. 2004;41(suppl 1):3-7.
8. Josephson CD, Abshire T. The new albumin-free recombinant factor VIII concentrates for treating hemophilia: Do they represent an actual incremental improvement? Clinical Advances in Hematology & Oncology. 2004;2:441-446.
9. Abshire T. Are oncogenes responsible for hemophilic arthropathy? Blood. 2004;104(7):1911-1912.
10. Abshire T. Textbook of Hemophilia. Transfusion. 2005;45(12):1981.
11. Abshire TC. Prophylaxis and von Willebrand's disease (vWD). Thromb Res., 2006 Mar 31: 118 Suppl 1:p S3-7.
12. Dunn AL, Abshire TC. Current issues in prophylactic therapy for persons with hemophilia. Acta Haematol. 2006;115(3-4):162-71.
13. Mannucci PM, Abshire T, Dimichele D, Santagostino E, Blanchette V. Inhibitor development, immune tolerance and prophylaxis in haemophilia A--the need for an evidence-based approach. Haemophilia. 2006 Jul;12(4):429-34.
14. Berntorp E, Abshire T; on behalf of the vWD PN steering committee. The von Willebrand Disease Prophylaxis Network (vWD PN): Exploring a treatment concept. Thromb Res. 2006;118(suppl 1):S19-22.
15. Josephson CD, Abshire TC. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophiliac A and B, and for von Willebrand disease. Best Pract Res Clin Haematol. 2006;19(1):35-49.
16. Abshire TC. Prophylaxis and von Willebrand's disease (vWD). Thromb Res. 2006;118 Suppl 1:S3-7.
17. Abshire T. Prevalence of von Willebrand disease among French Basque: clarity or confusion? InternationalMonitor on von Willebrand Disease. 2006;1:41-42(80th Anniversary issue).
18. Abshire TC. Inhibitors in hemophilia: nature or nurture? Blood. 2007;109:4596.
19. Abshire T. Haemophilia and Hemostasis: A Case-based Approach to Management. 2007: p 65, 97, 107, 171-72.
20. Abshire T. Diagnostic difficulties in patients with acquired von Willebrand syndrome. International Monitor on von Willebrand Disease. 2008;3:40-41.
21. Abshire T. Safety Update on Recombinant Factor VIIa in the Treatment of Congenital and Acquired Hemophilia. Semin Hematol. 2008 Apr;45(suppl 1):S3-S6.
22. Abshire T. Childhood ITP: can we venture below 20,000. Blood. 2008 Nov 15;112(10):3918-9.
23. Abshire TC. Diagnosis of type 1 VWD: can the clinical history trump laboratory findings? Pediatr Blood Cancer. 2009 Jan;52(1):7-8.
24. Kouides P, Federici AB, James AH, Berntorp E, Abshire T, Kreuz W. Diagnosis and management of inherited von Willebrand disease in the next decade: panel discussion. Thromb Res. 2009 Nov;124 Suppl 1:S20-1.
25. Abshire T. The role of prophylaxis in the management of von Willebrand disease: today and tomorrow. Thromb Res. 2009 Nov;124 Suppl 1:S15-9.
 
Non-Refereed Journal Publications/Original Papers
1. Josephson CD, Abshire TC. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease. Best Pract Res Clin Haematol. 2006;19(1):35-49.
2. Dunn AL, Abshire TC. Current issues in prophylactic therapy for persons with hemophilia. Acta Haematol. 2006;115(3-4):162-71.
3. Abshire TC. Prophylaxis and von Willebrand's disease (vWD). Thromb Res. 2006;118(suppl 1):S3-7.
4. Abshire TC. Diagnosis of type 1 VWD: can the clinical history trump laboratory findings? Pediatr Blood Cancer. 2009 Jan;52(1):7-8.
 
Abstracts
1. Abshire TC. Use of prophylaxis as routine management and surgical cover for patients with haemophilia. J Thromb Haemost (ISTH Annual Meeting Abstracts). 2003 Jul;1(suppl 1):S46.
2. Miller CH, Nix B, Benson E, Abshire TC. Platelet aggregation and ATP release in whole blood for diagnosis of bleeding disorders. J Thromb Haemost (ISTH Annual Meeting Abstracts). 2003 Jul;1(suppl 1):P1809.
3. Howard T, Machiah DM, Tran TT, Viel KR, Channell C, Soria JM, Ameri A, Iyer RV, Brown C, Doering C, Almasy L, Watts R, Davis J, Abshire TC. African-Americans Express Multiple Haplotypic Forms of the Wildtype Factor VIII (FVIII) Protein: A Possible Role for Pharmacogenetics in FVIII Inhibitor Development? Blood (ASH Annual Meeting Abstracts). 2004;104:384.
4. Brandao L, Briones M, Miller CH, White JG, Kauffman J, Abshire TC. Clinical and laboratory features of mild bleeding disorders. J Thromb Haemost (ISTH Annual Meeting Abstracts). 2005 Aug;3:P0260.
5. Dunn A, Abshire T, Balark K, Manco-Johnson M. Leukemia after P32 Radionuclide Synovectomy for Hemophilic Arthropathy. J Thromb Haemost (ISTH Annual Meeting Abstracts). 2005 Aug;3:2029.
6. Machiah DK, Howard T, Tran TT, Viel KR, Channell C, Soria JM, Ameri A, Iyer RV, Brown C, Doering C, Almawsy L, Watts R, Davis J, Abshire TC. The pharmacogenetics and inhibitor risk study: No significant differences found in the mutational spectrum of African-Americans with Hemophilia A. J Thromb Haemost (ISTH Annual Meeting Abstracts). 2005 Aug;3:P0642.
7. Eapen M, Raetz E, Zhang MJ, Muehlenbein C, Devidas M, Abshire T, Billett A, Homans A, Camitta B, Carroll W, Davies S. Outcomes after HLA-matched sibling transplants or chemotherapy in children with acute lymphoblastic leukemia in second remission: A collaborative study of the Children's Oncology Group (COG) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood (ASH Annual Meeting Abstracts). 2005 Nov 16;106(11):174.
8. Manco-Johnson MJ, Abshire TC, Brown D, Buchanan GR, Cohen AR, DiMichele D, Hoots WK, Leissinger C, McRedmond K, Nugent DJ, Shapiro AD, Thomas GA, Valentino LA, Riske B. Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency. Blood (ASH Annual Meeting Abstracts). 2005 Nov 16;106(11)3.
9. Howard TE, Machiah DK, Viel KR, Channel C, Ameri A, Iyer RV, Watts RG, Lutcher C, Davis J, Abshire TC, Almasy L. The pharmacogenetics and inhibitor risk (PIR) study: establishing the spectrum of factor (F)VIII gene (F8) mutations in African-American hemophilia a patients. Blood (ASH Annual Meeting Abstracts). 2005 Nov 16;106(11)3207.
10. Bennett CM, Bussel JB, Mueller BU, Abshire TC, Sawaf H, Moore TB, Loh ML, Rogers ZR, Feldman HA, Neufeld EJ, the Glaser Pediatric Research Network for the Pediatric ITP/Rituximab Study Group. Pharmacokinetics (PK) substudy of rituximab in a prospective clinical trial for pediatric chronic immune thrombocytopenic purpura (cITP). Blood (ASH Annual Meeting Abstracts). 2005 Nov 16;106(11):1243.
11. Shapiro A, Abshire T, Hernandez F, Gruppo R, Tarantino M, Warrier I, Schroth P, Spotts G, Retzios A, Ewenstein B. Efficacy and safety of ADVATE rAHF-PFM for perioperative management of hemostasis in previously treated children with hemophilia A. Haemophilia (WFH Annual Meeting Abstracts). 2006;12(suppl 2):13-22.
12. Hay CRM, Keegan J, Goldstone J, Hirsch S, Ewing N, Abshire T, DiMichele DM, for the International ITI Study Group. International immune tolerance (ITI) study: frequency of central venous line infection and effect on ITI outcome. Haemophilia (WFH Annual Meeting Abstracts). 2006;12(suppl 2):57-69.
13. Berntorp E, Abshire T, Carcao M, DiPaola J, Donfield S, Gill J, Kouides P, Kurnik K, Leebeek F, Lethagen S, Makris M, Mannucci P, Mathew P, Suiter T, Winikoff R. An international endeavor to define and evaluate regimens for prophylaxis in vWD. Haemophilia (WFH Annual Meeting Abstracts). 2006;12(suppl 2):137-143.
14. Soucie M, Kulkarni R, Abshire T, Hoots W, Curtis R, Drake J, Duffy N, Forsyth A, Key N, Konkle B, Kuebler E, Nielsen B. Hemophilia and inherited bleeding disorders in the first 2 years of life: diagnosis, mode of delivery and bleeding sites - a report from the baby Universal Data Collection (UDC) surveillance project of the Centers for Disease Control and Prevention. Haemophilia (WFH Annual Meeting Abstracts). 2006;12(suppl 2):148-154.
15. Manco-Johnson MJ, Abshire TC, Brown D, Buchanan GR, Cohen AR, DiMichele D, Hoots K, Leissinger C, McRedmond K, Nugent DJ, Shapiro AD, Thomas GA, Valentino LA, Riske B. Randomized, controlled, multi-year study to evaluate joint outcomes in young children using recombinant factor VIII (Kogenate FS). Haemophilia (WFH Annual Meeting Abstracts). 2006;12(suppl 2):13-22.
16. Ashrani A, Key N, Duffy N, Forsyth A, Geraghty S, Abshire T, Curtis R, Drake J, Hoots W, Kuebler E, Konkle B, Kulkarni R, Nielsen B, Soucie J. Characteristics of and risk factors for septic arthritis in males with hemophilia. Haemophilia (WFH Annual Meeting Abstracts). 2006;12(suppl 2):51-56.
17. Abshire T, Hoots K, Kessler C, MacFarlane D, Gergman G. Preclinical and clinical experiences with a recombinant porcine FVIII product. Haemophilia (WFH Annual Meeting Abstracts). 2006;12(suppl 2):97-101.
18. Howard TE, Viel KR, Fernstrom KM, Deshpande S, Ameri A, Ali MS, Channell C, Iyer RV, Watts RG, Lutcher C, Nakaya S, Kasper CK, Thompson AR, Abshire TC, Almasy L. Allelically Mismatched Replacement Therapy Due to Common African-Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia-A Patients of African-Descent. Blood (ASH Annual Meeting Abstracts). 2006 Nov;108:765.
19. Howard TE, Viel KR, Fernstrom KM, Deshpande S, Ameri A, Ali MS, Channell C, Iyer RV, Watts RG, Lutcher C, Nakaya S, Kasper CK, Thompson AR, Abshire TC, Almasy L. Allelically Mismatched Replacement Therapy Due to Common African-Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia-A Patients of African-Descent. Blood (ASH Annual Meeting Abstracts). 2006 Nov;108:765.
20. Soucie JM, miller CH, Creary M, Hooper WC, Abshire TC, Brettler DB, Bockenstedt P, Dipoala J, Massey G, Neff A, Shapiro A, Tarantino M, Wicklund BM, Dimichele D, UDC Working Group. U.S. Inhibitor Pilot Project: Study Design and Methods Validation. J Thromb Haemost (ISTH Annual Meeting Abstracts). 2007 Jul;5(suppl 2):PT-118.
21. Miller CH, Platt SJ, Abshire T, Brettler D, Brokenstedt P, DiPaola J, Massey G, Neff A, Shapiro A, Tarantino M, Wicklund B, Creary M, Soucie MJ. Experience with a Modified Nijmegen-Bethesda Method for Measurement of Inhibitors in Hemophilia Patients: The CDC Inhibitor Surveillance Pilot Project. Blood (ASH Annual Meeting Abstracts). 2007 Nov;110:1156.
22. Bellissimo DB, Christopherson PA, Haberichter SL, Flood VH, Gill JC, Friedman KD, Abshire TC, DiPaola, Hoots WK, Leissinger C, Lusher JM, Ragni AD, Shapiro AD, Montgomery RR. Novel VWF Sequence Variations Identified in Normal Controls and Index Cases Enrolled in the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB-VWD). Blood (ASH Annual Meeting Abstracts). 2007 Nov;110:709.
23. Flood VH, Kautza BC, Miller CA, Branchford BR, Gill JC, Haberichter SL, Morateck PA, Christopherson, PA, Perry CL, Friedman KD, Bellissimo DB, Abshire TC, DiPaola JA, Hoots WK, Lessinger C, Lusher JM, Ragni AD, Shapiro AD, Lillicrap D, Goodeve AC, Peake IR, Montgomery RR. Common VWF Haplotypes in normal African-American and Caucasians Recruited into the ZPMCB-VWD and Their Impact on VWF Laboratory Testing. Blood (ASH Annual Meeting Abstracts). 2007 Nov;110:714.
24. Creary M, Soucie JM, Miller CH, Hooper WC, Abshire TC, Brettler DB, Pokenstedt PL, DiPaola JA, Massey G, Neff A, Shapiro A, Tarantino M, Wicklund, Dimichele D. U.S. inhibitor Pilot Project: Participant Characteristics and Infusion Log Adherence. Blood (ASH Annual Meeting Abstracts). 2007 Nov;110:1162.
25. Haberichter SL, Christopherson PA, Perry CL, Lee A, Morateck PA, Bellissimo DB, Gill JC, Abshire TC, DiPaola JA, Hoots WK, Leissinger C, lusher LM, Ragni MV, Shapiro AD, Montgomery RR. The Prevalence of Reduced VWF Survival Phenotype (Type 1C VWD) in Type1 Index Cases Recruited into the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB-VWD). Blood (ASH Annual Meeting Abstracts). 2007 Nov;110:2133.
26. Flood VH, Kautza BC, Miller CA, Branchford BR, Gill JC, Haberichter SL, Morateck PA, Christopherson PA, Perry CL, Friedman KD, Bellissimo DB, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro A, Lillicrap D, Goodeve AC, Peake IR, Montgomery RR. Common VWF Haplotypes in Normal African-Americans and Caucasians Recruited into the ZPMCB-VWD and Their Impact on VWF Laboratory Testing. Blood (ASH Annual Meeting Abstracts). 2007 Nov;110:714.
27. Haberichter SL, Christopherson PA, Perry CL, Lee A, Morateck PA, Bellissimo DB, Gill JC, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro Ad, Montgomery RR. The Prevalence of Reduced VWF Survival Phenotype (Type 1C VWD) in Type 1 Index Cases Recruited into the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB - VWD). Blood (ASH Annual Meeting Abstracts). 2007 Nov;110:2133.
28. Abshire T. Von Willebrand disease, manifestation, and treatment. The VWD prophylaxis network (PN). Haemophilia (WFH Annual Meeting Abstracts). 2008 June;14(suppl 2):18 S 05.
29. Miller CH, Hooper C, Abshire TC, Bockenstedt PL, Brettler DB, Di Paola J, Massey G, Neff AT, Shapiro AD, Tarantino M, Wicklund BM, Manco-Johnson MJ, Dunn AL, Knoll C, Creary M, Benson J, Ellingsen D, Driggers J, Soucie JM. Factor VIII and Factor IX Mutation analysis in 600 U.S. Hemophilia Patients: Correlation of Mutation Type with History of Inhibitor. Blood (ASH Annual Meeting Abstracts). Nov 2008;112:1017.
30. Miller CH, Hooper C, Benson J, Ellingsen D, Driggers J, Abshire TC, Bockenstedt PL, Brettler DB, Di Paola J, Massey G, Neff AT, Shapiro AD, Tarantino M, Wicklund BM, Manco-Johnson MJ, Dunn AL, Knoll C, Creary M, Soucie JM. Novel factor VIII mutations in US hemophilia patients: relationship to ethnicity and inhibitor history. J Thromb Haemost (ISTH Annual Meeting Abstracts). 2009 July;7(suppl 2):PP-MO-596.
31. Soucie JM, Creary M, Abshire TC, Brettler DB, Bockenstedt PL, di Paola J, Massey G, Neff AT, Shapiro AD, Tarantino M, Wicklund BM, Manco-Jonson MJ, Dunn AL, Knill C, Platt SJ, Driggers J, Ellingsen D, Benson J, Hooper C, Miller CH. Inhibitor Surveillance and Mutation Analysis in Hemophilia B Patients. J Thromb Haemost (ISTH Annual Meeting Abstracts). 2009;7(Suppl 2):PP-WE-613.
32. Goldenberg NA, Tripputi M, Crowther MA, Abshire TC, DiMichele DM, Manco-Johnson MJ, Hiatt WR. The Kids-DOTT Trial: Novel Aspects of the 'Parallel Cohort RCT' Design and Its Application to the Investigation of Duration of Anticoagulant Therapy for Pediatric Venous Thromboembolism. Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:4169.
33. Kempton CL, Soucie JM, Miller CH, Hooper C, Escobar MA, Reding MT, Cohen AJ, Key NS, Thompson AR, Manco-Johnson MJ, Abshire TC. Risk Factors for Inhibitor Development in Mild and Moderate Hemophilia A: A Case-Control Study. Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:1234.
34. Berntorp E, Abshire TC, Federici AB. Regular Replacement Therapy as Prophylaxis in Severe Forms of Von Willebrand Disease: Initial Results from the Von Willebrand Disease Prophylaxis Network (VWD PN) Study Group. Blood (ASH Annual Meeting Abstracts). 2010 Nov;116:109.
35. Markris M, Federici, Yee T, Abshire TC, Berntorp E, Mannucci PM. The Diagnosis and Management of Von Willebrand Disease (VWD) Associated Angiodysplasia. J Thromb Haemost (ISTH Annual Meeting Abstracts). 2011 July;9(suppl 2):WE-457.